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The effect of Ab25–35 peptide, in its ﬁbrillar and non-ﬁbrillar forms, on ganglioside expression in
organotypic hippocampal slice cultures was investigated. Gangliosides were endogenously labeled with
D-[1-C14] galactose and results showed that Ab25–35 affected ganglioside expression, depending on the
peptide aggregation state, that is, ﬁbrillar Ab25–35 caused an increase in GM3 labeling and a reduction in
GD1b labeling, whereas the non-ﬁbrillar form was able to enhance GM1 expression. Interestingly, GM1
exhibited a neuroprotective effect in this organotypic model, since pre-treatment of the hippocampal
slices with GM1 10 lM was able to prevent the toxicity triggered by the ﬁbrillar Ab25–35, when
measured by propidium iodide uptake protocol. With the purpose of further investigating a possible
mechanism of action, we analyzed the effect of GM1 treatment (1, 6, 12 and 24 h) upon the Ab-induced
alterations on GSK3b dephosphorylation/activation state. Results demonstrated an important effect after
24-h incubation, with GM1 preventing the Ab-induced dephosphorylation (activation) of GSK3b, a signal-
ing pathway involved in apoptosis triggering and neuronal death in models of Alzheimer’s disease. Taken
together, present results provide a new and important support for ganglioside participation in develop-
ment of Alzheimer’s disease experimental models and suggest a protective role for GM1 in Ab-induced
toxicity. This may be useful for designing new therapeutic strategies for Alzheimer’s treatment.
 2011 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Gangliosides are a large family of glycosphingolipids, structur-
ally characterized by a ceramide hydrophobic core linked to an oli-
gosaccharide chain, which usually contains at least one sialic acid
residue. They are synthesized in the Golgi apparatus through
sequential glycosylation and sialylation of a glucosylceramide moi-
ety (Tettamanti, 2004).
Gangliosides amount to 10% of the brain membrane lipid con-
tent and act as the functional lipid component of the membrane
rafts; they play important biochemical roles in cell biology, taking
part in some processes like cell differentiation and maturation,
synaptogenesis, intercellular communication, neuronal plasticity,
and cell death/survival processes. This plethora of effects depends
on the expressed ganglioside proﬁle, the localization and organiza-lsevier OA license. 
uímica, Instituto de Ciências
do Sul, Rua Ramiro Barcelos,
Tel.: +55 51 3308 5550; fax:tion of these lipids inside and across the membrane and on the bio-
logical moment during which they are expressed (Svennerholm,
1980; Vyas and Schnaar, 2001; Mocchetti, 2005; Ichikawa et al.,
2009; Lopez and Schnaar, 2009).
It has been reported that little modiﬁcations in ganglioside pro-
ﬁle and/or distribution could affect cellular biology, and therefore
it is possible to hypothesize that gangliosides are involved in the
development and evolution of several diseases. Alterations in gan-
glioside proﬁle and/or distribution in models of hypoxia ischemia
(Trindade et al., 2001; Ramirez et al., 2003), organic acidurias
(Trindade et al., 2002), hypermethioninemia (Stefanello et al.,
2007) and hyperprolinemia (Vianna et al., 2008) have been previ-
ously demonstrated. Several other studies have attributed the par-
ticipation of gangliosides in the development of neurodegenerative
disorders like Alzheimer’s disease (Yanagisawa, 2007; Ariga et al.,
2008; Zhang et al., 2009; Eckert et al., 2010; Harris and Milton,
2010; Haughey et al., 2010). Nevertheless, the exact role of such
lipids in disease outcome remains poorly understood.
Alzheimer’s disease is a neurodegenerative disorder character-
ized by a progressive and still irreversible cognitive loss. Although
it was ﬁrstly described in 1906, little is known about its
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cascade, which consists of the production and extracellular deposi-
tion of an amyloid b-peptide (Ab). The produced peptide may re-
main in a soluble form (monomer, dimmer or oligomer) or follow
on an aggregation process which involves the formation of peptide
insoluble ﬁbril forms. Although the ﬁbrils represent the preferen-
tial form of Ab deposition and are considered the main component
of the senile plaques (a classic histopathology marker of Alzhei-
mer’s disease), both insoluble and soluble forms of the peptide
are potentially neurotoxic. However, the exact mechanisms
regulating Ab formation, as well as those involved in the cellular
response against this peptide, remain unclear (Suh and Checler,
2002; Pimplikar, 2009; Walsh and Selkoe, 2007). The natural Ab
peptides are composed of 39–43 amino acid residues. Neverthe-
less, their shorter synthetic analog, Ab25–35, which contains the
amino acid sequence 25–35 of its natural counterparts, seems to
trigger similar toxicity mechanisms (El Khoury et al., 1996; Yan
et al., 1996; Guan et al., 2001; Qi et al., 2005; Frozza et al., 2009)
and, just as the natural Ab peptides, is able to aggregate into ﬁbrils
(Kowall et al., 1992). Consequently, Ab25–35 is a convenient tool
for the investigation of neurotoxic mechanisms involved in Alzhei-
mer’s disease.
Since the production of a Ab peptide occurs in the biological
membranes, and taking into account the occurrence of an interac-
tion between Ab and GM1 ganglioside, which in turn could facilitate
or even accelerate the ﬁbril formation, a positive relationship
between GM1 expression and the amyloid cascade processing has
been proposed (Matsuzaki, 2007; Yanagisawa, 2007; Mikhalyov
et al., 2010). On the other hand, many studies suggest a neuropro-
tective role for GM1 in several disease models (Krajnc et al., 1994;
Lazzaro et al., 1994; Augustinsson et al., 1997; Svennerholm et al.,
2002; Sokolova et al., 2007).
Several studies have addressed a pivotal role for GSK3b signal-
ing pathway in neuronal death and disease development observed
in Alzheimer’s (Hooper et al., 2008; Hernández et al., 2009a,b). An
amyloid induced activation (dephosphorylation) of GSK3b has
been shown in some experimental models, and a correlation be-
tween its activity and the neurotoxicity triggered by this peptide.
Koh et al. (2008) proposed the analysis of GSK3b phosphorylation
as a biochemical parameter in the investigation of possible neuro-
protective drugs.
Organotypic hippocampal slice cultures are a considerable
alternative to animal model experiments. Cultured slices maintain
the cell architecture and interneuronal connections, allowing for a
long in vitro survival period (Stoppini et al., 1991; Tavares et al.,
2001). They have been used to investigate molecular mechanisms
involved in cytotoxicity, such as the ones that are determined by
oxygen and glucose deprivation (Valentim et al., 2003; Cimarosti
et al., 2005; Zamin et al., 2006; Horn et al., 2005, 2009) and Ab tox-
icity (Ito et al., 2003; Nassif et al., 2007; Frozza et al., 2009). This
methodology has also been used for neuroprotection strategy eval-
uations (Cimarosti et al., 2006; Simão et al., 2009; Bernardi et al.,
2010; Hoppe et al., 2010).
The aim of this study was to examine the effect of Ab treatment
to organotypic hippocampal slice cultures on ganglioside expres-
sion, as well as the GM1 effect on Ab-induced toxicity, as assessed
by cellular death and GSK3b phosphorylation.2. Experimental procedures
2.1. Materials
Acrylamide, bisacrylamide, SDS and b-mercaptoethanol used in
sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS–
PAGE) were obtained from Sigma (St. Louis, MO, USA) as well asAb25–35, Ab35–25, propidium iodide (PI), standard glycolipids
and the ganglioside GM1 used in culture incubation. Polyclonal
antibodies were purchased from Cell Signaling Technology
(Beverly, MA, USA). Anti-rabbit IgG peroxidase-conjugated and
reagents to detect chemiluminescence (ECL) were purchased from
Amersham Pharmacia Biotech (Piscataway, NJ, USA). Millicell cul-
ture inserts (Millicell-CM, 0.4 lm) were obtained from Millipore
(Millipore, Bedford, MA, USA), 6-well culture plates were from
TPP (Tissue culture test plates TPP, Switzerland). Culture medium,
HBSS, fungizone and heat inactivated horse serum were obtained
from GIBCO (Grand Island, NY, USA). Gentamicin was from Scher-
ing–Plough (Rio de Janeiro, Brazil). D-[1-C14] galactose (57 mCi/
mmol) was obtained from Amersham Life Science (Buckingham-
shire, UK). Silicagel high performance thin layer chromatography
(HPTLC) plates were supplied by Merck (Darmstadt, Germany).
All other chemicals and solvents used were of analytical grade.
2.2. Organotypic hippocampal slice cultures
All animal procedures were approved by local Animal Care
Committee and are in accordance with the NIH Guide for the care
and use of laboratory animals. Organotypic hippocampal slice cul-
tures were prepared according to the method of Stoppini et al.
(1991), with modiﬁcations (Valentim et al., 2003; Cimarosti
et al., 2005; Horn et al., 2005; Frozza et al., 2009). Brieﬂy, 400-
lm-thick hippocampal slices were prepared from 6 to 8-day-old
male Wistar rats using a McIlwain tissue chopper and separated
in ice-cold Hank’s balanced salt solution (HBSS) composed of
(mM): glucose 36, CaCl2 1.26, KCl 5.36, NaCl 136.89, KH2PO4
0.44, Na2HPO4 0.34, MgCl2 0.49, MgSO4 0.44, HEPES 25; fungizone
1% and gentamicin 0.1 mg/mL, pH 7.2. The slices were placed on
Millicell culture insert and the inserts were transferred to a 6-well
culture plate. Each well contained 1 mL of tissue culture medium
consisting of 50% minimum essential medium, 25% HBSS, 25% heat
inactivated horse serum supplemented with (mM, ﬁnal concentra-
tion): glucose 36, HEPES 25 and NaHCO3 4; fungizone 1% and gen-
tamicin 0.1 mg/mL, pH 7.3. Organotypic cultures were maintained
in a humidiﬁed incubator gasiﬁed with 5% CO2 atmosphere at 37 C
for 30 days. Culture medium was changed three times a week.
2.3. Ab25–35 peptide preparation and culture treatments
Ab25–35 and Ab35–25 (reverse peptide) stock solutions
(675 lM) were prepared in sterile distilled water and stored at
20 C. To obtain the ﬁbrillar form of Ab2535 peptide, an aliquot
of the stock solution was incubated under 37 C during the 4 days
preceding its use in culture (Casal et al., 2004). The so-called non-
ﬁbrillar Ab corresponds to the peptide that was not subjected to
the aforementioned activation process and was therefore added
to the culture directly from stock solution. On the 28th in vitro
day, the medium was replaced by a serum reduced medium
(2.5%) into which 25 lM of ﬁbrillar/non-ﬁbrillar Ab25–35 or
Ab35–25 was added or not (control slices). Previous experiments
showed that this concentration (25 lM) of Ab25–35 had the most
toxic effect (data not shown), at least for the ﬁbrillar peptide form.
2.4. Quantiﬁcation of cell death
Cellular damage was assessed by ﬂuorescent image analysis of
propidium iodide (PI) uptake (Noraberg et al., 1999). One hour
before the end of the treatments, which means after 47 h of
Ab25–35 or Ab35–25 exposure, 7.5 lM of PI was added to the med-
ium and incubated for 1 h. PI uptake is indicative of signiﬁcant
membrane injury (Macklis and Madison, 1990). Cultures were
observed with an inverted microscope (Nikon Eclipse TE 300) using
a standard rhodamine ﬁlter set. Images were captured and then
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After capture of images, the area where PI ﬂuorescence
(transformed in pixels) was detectable above the background
was analyzed using the ‘‘density slice’’ option of Scioncorp Soft-
ware through the division of PI ﬂuorescence by the total area of
the slice (Valentim et al., 2003). The PI intensity, meaning cell
death, was expressed as a percentage of ﬂuorescence:
Celldeath ð%Þ ¼ Fd=F0  100
where Fd is the PI uptake ﬂuorescence of dead area of hippocampal
slices and F0 is the total area of each hippocampal slice.
2.5. Metabolic ganglioside labeling
On the 29th in-vitro day, D-[1-C14] galactose was added to the
serum reduced (2.5%) culture medium, to a ﬁnal concentration of
1 lCi/ml, and the slices were maintained incubated during the last
24 h of culture. Subsequent to the death analysis, the slices were
removed from the plates, washed three times with PBS buffer,
and submitted to lipid extraction protocol.
2.6. Lipid extraction
Each of the two washed slices were submitted to lipid extrac-
tion using sequentially the mixture of chloroform:methanol (C:M
2:1, v/v) and chloroform:methanol (C:M 1:2, v/v). The C:M extracts
were combined and this pool was directly freed from water-
soluble contaminants by passing through a Sephadex G-25 column
equilibrated in C:M:Water (60:30:4.5) (Andrade et al., 2003).
2.7. Chromatography and ﬂuorography
The puriﬁed lipid extracts (±3000 cpm) were evaporated under
N2 and run on HPTLC silica gel 60 plates (Merck), with two succes-
sive solvent systems: ﬁrst, chloroform/methanol (4:1, v/v) and sec-
ond, chloroform/methanol/0.25%aqueous CaCl2 (60:36:8, v/v). The
second migration was run in a TLC tank designed by Nores et al.
(1994). Radioactive glycosphingolipids were visualized by expo-
sure to a radiographic ﬁlm (Kodak X-Omat AR) at 80 C, usually
for 3 weeks, and their relative contribution was determined by
densitometric scanning of the X-ray ﬁlm in a Geliance 600 Image
System (PerkinElmer, USA). Standard gangliosides were visualized
by exposure to resorcinol–HCl (Svennerholm, 1957; Lake and
Goodwin, 1976).
2.8. GM1 ganglioside culture treatments
GM1 solution was prepared in a sterile saline buffer. In order to
investigate the effect of this ganglioside on the Ab-induced toxicity,
a volume of this solution was added to the medium (at a ﬁnal con-
centration of 10 lM) 48 h before adding Ab25–35 peptide, and
again at the moment of Ab2535 incubation (Ghidoni et al.,
1989). Forty-eight hours after the peptide incubation, slices were
submitted to death analysis by IP uptake. For Western-blot analy-
sis of signaling proteins, culture slices were treated with GM1
(10 lM) and/or ﬁbrillar Ab25–35 (25 lM) for 1, 6, 12, or 24 h.
2.9. Western blotting assay
After obtaining the ﬂuorescent images for cell death analysis,
slices were homogenized in lyses buffer (4% sodium dodecylsul-
fate, 2 mM EDTA, 50 mM Tris). Aliquots were taken for protein
determination and b-mercaptoethanol was added to a ﬁnal con-
centration of 5% in order to prevent protein oxidation. Samples
containing 50 lg of protein were resolved by 10% SDS–PAGE. Pro-
teins were electro transferred to nitrocellulose membranes using asemi-dry transfer apparatus (Bio-Rad, Trans-Blot SD). After 1-h
incubation at 4 C in blocking solution containing 5% non-fat milk
and 0.1% Tween-20 in Tris–buffered saline (TBS; 50 mM Tris–HCl,
1.5% NaCl, pH 7.4), membranes were incubated overnight with
the appropriate primary antibody diluted in the same blocking
solution. Primary antibodies against the following proteins were
used: anti-phospho GSK-3b (Ser9) (pGSK-3b, 1:1000), anti-GSK-
3b (1:1000), and anti-b-actin (1:1000). The membranes were then
incubated with horseradish peroxidase-conjugated anti-rabbit
antibody (1:1000). The chemioluminescence (ECL) was detected
using X-ray ﬁlms (Kodak X-Omat). Films were scanned and the
percentage of band intensity was analyzed using Optiquant soft-
ware (Packard Instrument). For each experiment, the test groups
(treated with GM1, ﬁbrillar Ab25–35, or simultaneously treated
with both GM1 and ﬁbrillar Ab25–35), were compared to control
cultures (exposed neither to Ab25–35 nor to GM1), which were
considered 100%, thus assuring the same signal intensity for con-
trol and test groups. Data are expressed as percentage of phosphor-
ylated protein for GSK3b, which was obtained by the ratio of the
phospho-protein (pGSK-3b) with its whole amount (GSK-3b) (Froz-
za et al., 2009). Protein contents were measured by the method of
Peterson (1977). In order to normalize the value of protein, we de-
tected b-actin in the same analysis.
2.10. Statistical analysis
Data are expressed as mean ± S.D. One-way or two-way analysis
of variance (ANOVA) was applied to the means to determine statis-
tical differences between experimental groups. Post hoc compari-
sons were performed using the Tukey test for multiple
comparisons. Differences between mean values were considered
signiﬁcant when p < 0.05.3. Results
3.1. Toxicity induced by the different Ab25–35 peptide forms in
organotypic hippocampal slice cultures
Culture exposure to ﬁbrillar Ab25–35 (25 lM) caused marked
ﬂuorescence in hippocampal slices after 48 h of treatment, indicat-
ing a high incorporation of PI, which in turn means peptide-in-
duced cellular death. On the other hand, the non-ﬁbrillar form of
Ab25–35 (25 lM) caused no signiﬁcant cellular death to the hippo-
campal slices, as observed in Fig. 1A. The quantiﬁcation of PI incor-
poration is shown in Fig. 1B. We did not observe any increase in
ﬂuorescence in hippocampal slices exposed to the reverse se-
quence of peptides (Ab35–25) at 25 lM (data not shown).
3.2. Ab25–35 peptide effects upon ganglioside expression
Although neither the ﬁbrillar nor the non-ﬁbrillar b-amyloid
forms were able to cause any change to total radiolabeling
(Fig. 2A), chromatographic and densitometric analysis revealed
that they exerted distinct effects on the proﬁle and distribution
of expressed gangliosides. While non-ﬁbrillar Ab caused a signiﬁ-
cant increase in GM1 expression (p < 0.05), the ﬁbrillar form in-
duced an increase in GM3 (p < 0.05) and a decrease in GD1b
(p < 0.05) metabolic labeling (Fig. 2B and C). We did not observe
any effect of the reverse sequence of peptides (Ab35–25) upon
ganglioside expression (data not shown).
3.3. Analysis of GM1 effect on Ab25–35-induced cell death
To test for a possible GM1 neuroprotective effect in organotypic
hippocampal slice cultures, we challenged the ﬁbrillar Ab-induced
Fig. 1. Toxicity induced after 48-h exposure of organotypic hippocampal cultures to non-ﬁbrillar and ﬁbrillar Ab25–35 peptide (25 lM): (A) representative photomicrographs
of slices stained with PI at the end of treatment; (B) quantitative analysis of hippocampal damage just after each treatment with non-ﬁbrillar Ab25–35 (non-ﬁbrillar Ab) and
with ﬁbrillar Ab25–35 (ﬁbrillar Ab), respectively. Bars represent the mean + S.D., n = 8. ⁄Signiﬁcantly different from control cultures (one-way ANOVA followed by Tukey test,
p < 0.05).
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of culture slices with 10 lM GM1 (48 h prior to Ab exposure and
during the 48 h of this peptide incubation) was able to signiﬁcantly
prevent the peptide-induced cell death.3.4. Effect of GM1 upon ﬁbrillar Ab-induced alteration of GSK3b
phosphorylation state
To further investigate one of the possible mechanisms involved
on neuroprotective effect of GM1 just reported, we analyzed GM1
effect upon Ab induced alteration in GSK3b phosphorylation after
1, 6, 12 and 24 h. Results show no effect of GM1 or ﬁbrillar
Ab25–35 treatment after 1 h of treatment. Nevertheless, 6 h of
co-treatment with GM1 and Ab25–35 caused a signiﬁcant increase
in GSK3b phosphorylation. After 12 h of GM1 treatment we ob-
served a decrease (p < 0.05) in GSK3b phosphorylation, and after
24 h of treatment it was shown that GM1 was able to augment
GSK3b phosphorylation; moreover the co-treatment with GM1
and Ab25–35 was able to prevent b-amyloid-induced reduction
in GSK3b phosphorylation state (Fig. 4).4. Discussion
Organotypic cultures, in spite of some limitations, are a good
alternative to in vivomodels, since they provide a good experimen-
tal access to mimic pathophysiological pathways in living tissues,
and because they preserve the cell organization and tissue archi-tecture (Stoppini et al., 1991; Tavares et al., 2001; Holopainen,
2005; Cimarosti et al., 2006; Horn et al., 2009; Simão et al., 2009;
Hoppe et al., 2010). Using this model, we could observe that the
Ab induced death depended on its aggregation state, since the
non-ﬁbrillar peptide form was unable to trigger toxicity, or at least
the toxicity as measured by PI uptake protocols (Fig. 1). Even
though the main limitation observed in this in vitro technique is
the variation, which is inherent in this model, we believe in the
reliability of our results, since we performed the experiments com-
paring the effect of Ab-peptide and/or the effect of GM1, using slice
culture of the same animal. Nevertheless our results showed strong
toxic effect of Ab and a notable neuroprotective effect of GM1.
Taking into account a considerable number of studies suggest-
ing a role of gangliosides and membrane lipid dynamics in the
amyloid cascade modulation, as well as a participation of these
lipids in the toxicity mechanisms triggered by amyloid peptide,
the present study has investigated the effect of Ab25–35, in its
ﬁbrillar or non-ﬁbrillar forms, upon ganglioside expression in a
model of hippocampal organotypic cultures (Yanagisawa, 2007;
Ariga et al., 2008; Zhang et al., 2009; Eckert et al., 2010; Harris
and Milton, 2010; Haughey et al., 2010).
Our results ﬁrstly demonstrate an Ab25–35 effect on ganglio-
side expression, which seemed to depend on the peptide aggrega-
tion state. Whereas ﬁbrillar Ab25–35 caused an increase in GM3
and a decrease in GD1b metabolic labeling, its non-ﬁbrillar form
was able to enhance GM1 expression (Fig. 2B and C).
Considering that GM3 is a ganglioside usually associated with
apoptotic mechanisms, at least when expressed in mature neuro-
Fig. 2. Effect of non-ﬁbrillar and ﬁbrillar forms Ab25–35 on the proﬁle and distribution of radiolabeled ganglioside species: (A) quantiﬁcation of total ganglioside
radiolabeling (measured as cpm/lg protein) obtained from organotypic hippocampal slice cultures exposed either to non-ﬁbrillar Ab25–35 (non-ﬁbrillar Ab) or ﬁbrillar
Ab25–35 (Fibrillar Ab). Gangliosides were extracted and puriﬁed with sephadex G-25 as described in Material and Methods. Bars represent the mean + S.D., n = 8. (one-way
ANOVA followed by Tukey test, p < 0.05); (B) high performance thin layer-autoradiography of D-[1-C14] galactose labeled endogenous gangliosides from organotypic
hippocampal slice cultures exposed to non-ﬁbrillar Ab, or ﬁbrillar Ab, or not exposed (control). Gangliosides were extracted, puriﬁed with sephadex G-25 and analyzed by
HPTLC, as described in experimental procedures. The position of co-chromatographed ganglioside standards is indicated; present results are representative of eight
independent experiments; (C) ganglioside distribution in organotypic hippocampal slice cultures exposed to non-ﬁbrillar Ab, or ﬁbrillar Ab, or not exposed (control). Results
correspond to densitometric analysis of HPLC-autoradiographies as shown in Fig. 2A. Bars express individual ganglioside as a percentage of the total radioactivity
incorporated into all ganglioside bands. Results showmean percentage + S.D. ⁄Signiﬁcantly different from control cultures (one-way ANOVA followed by Tukey test, p < 0.05).
652 F. Kreutz et al. / Neurochemistry International 59 (2011) 648–655nal cells (Sohn et al., 2006; Valaperta et al., 2006), and taking into
account an anti-apoptotic effect attributed to GD1b (Chen et al.,
2005), the enhancement in GM3 expression as well as the decrease
in GD1b expression, as a consequent of ﬁbrillar Ab25–35 incuba-
tion, can be suggested to take part in the toxic mechanisms trig-
gered by this peptide.
GM1, in turn, is a ganglioside usually associated with neuro-
protective effects. The exact mechanism involved in its neuropro-
tective action is not completely understood, however GM1 is able
to enhance/potentiate neurotrophin release and action (Rabin
et al., 2002; Mocchetti, 2005), to exert antioxidant effects (Fighera
et al., 2004; Furian et al., 2007; Gavella et al., 2007), to prevent/re-
vert glutamate induced excitotoxicity (Cunha et al., 1999), and to
modulate some signaling pathways involved in death/survival pro-
cesses (Mutoh et al., 1995; Pitto et al., 1998; Lili et al., 2005;
Duchemin et al., 2002, 2008).
On the other hand, several studies have attributed a participa-
tion in the mechanisms of Ab aggregation to GM1 since the inter-
action of the peptide with this ganglioside could act as a seed for
the aggregation process, accelerating or even potentiating its ﬁbril-
lation on membrane surfaces. This effect, however, seems to
depend on a clustering of this ganglioside into membrane microdo-
mains (lipid rafts) (Matsuzaki, 2007; Yanagisawa, 2007), as well ason the pH and ionic concentration of the medium (McLaurin et al.,
1998). Besides that, other studies have suggested a participation of
GM1 ganglioside in maturation of Amyloid Precursor Protein (APP),
affecting its localization on membrane surface, and therefore, pos-
itively modulating Ab production (Ehehalt et al., 2003; Zha et al.,
2004; Zhang et al., 2009).
To further investigate the role of this ganglioside (neuroprotec-
tive or not) in the present model, we performed experiments con-
sisting in the treatment of slices cultures with a saline GM1
solution, in order to assess a possible effect of this ganglioside upon
the Ab25–35 induced toxicity. Considering that just ﬁbrillar Ab25–
35 was able to trigger toxicity in our model, we have chosen this
peptide form to perform the neuroprotective investigation. The
pretreatment of slices with 10 lM GM1, 48 h previous to Ab25–
35 addition, was able to signiﬁcantly prevent the amyloid toxicity
measured after 48 h of amyloid incubation, as the PI uptake exper-
iments have demonstrated (Fig. 3).
Several studies have indicated the existence of a link among Ab
toxicity, progression of Alzheimer’s disease, and the activation of
the GSK3b signaling pathway. This signaling pathway exerts an
important effect on neurons, triggering the activation of cell death
processes that could include oxidative stress induction and apop-
tosis response activation. In models of Alzheimer’s disease, GSK3b
Fig. 3. Effect of GM1 treatment on ﬁbrillar Ab25–35-induced cell death: Slices were treated or not with 10 lM GM1 from the 26th in vitro day; on the 28th in vitro day,
ﬁbrillar Ab25–35 was added to the medium, and cell death was analyzed after 48 h of its incubation by PI uptake. Control cultured slices received neither GM1 nor amyloid–
peptide. (A) Representative photomicrographs of slices stained with PI at the end of treatment; (B) quantitative analysis of hippocampal damage. Bars represent mean + S.D.
of cell death, n = 5. (⁄) Signiﬁcantly different from control cultures; (#) signiﬁcantly different from Ab25–35 treated slices (two-way ANOVA followed by Tukey test, p < 0.05).
Fig. 4. Effect of 10 lM GM1 treatment on ﬁbrillar Ab25–35-induced alterations of GSK3b phosphorylation state: (A) representative Western blotting of phospho-GSK3b and
GSK3b after each treatment; (B) histograms representing the quantitative Western blotting analysis of GSK3b phosphorylation state. Densitometric values obtained to
phospho- and total-GSK3b were ﬁrst normalized to their respective controls; control values are shown as the horizontal clotted line. Data are expressed as a ratio of the
normalized phospho-GSK3b/GSK3b relation and bars represent the mean + S.D., n = 3 for 1, 6 and 12-h treatments, and n = 5 for 24-h treatment. (⁄) Signiﬁcantly different from
respective control culture; (#) signiﬁcantly different from respective ﬁbrillar Ab25–35 treated group (two-way ANOVA followed by Tukey test, p < 0.05).
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represent a link between Ab production/aggregation and the pos-
terior hyper-phosphorylation of tau protein, which in turn involves
the development of other important histopathology marker of Alz-
heimer’s disease, the neuroﬁbrillary tangles (Hooper et al., 2008;
Hernández et al., 2009a,b). Also, there is evidence that GSK3b acti-
vation, as measured by its phosphorylation state, could be useful as
a biochemical marker for the study of neuroprotective drugs, i.e.,drugs able to inhibit the Ab-induced activation of GSK3b could be
considered as potential neuroprotective ones (Koh et al., 2008; Avi-
la et al., 2010).
Thus, in order to further analyze the neuroprotective potential
of GM1 in our model, and to propose a possible mechanism by
which this ganglioside could trigger its neuroprotective action,
we investigated the effect of GM1, in a 10 lM concentration, upon
the Ab-induced alterations of GSK3b phosphorylation state (Fig. 4).
654 F. Kreutz et al. / Neurochemistry International 59 (2011) 648–655Although after 1 h of incubation no alteration was observed in
GSK3b phosphorylation, neither with GM1 nor Ab25–35, a longer
period of incubation (6 h) revealed that the co-treatment with
GM1 and Ab25–35 was able to increase GSK3b phosphorylation.
After 12 h of GM1 treatment, a decrease in GSK3b phosphorylation
was veriﬁed. Most importantly, however, it was observed that GM1
was able to reverse the dephosphorylation/activation of GSK3b
(p < 0.05) detected after 24 h of Ab25–35 incubation.
Our results demonstrate a potential neuroprotective effect of
GM1 ganglioside, which suggests that the Ab-induced alterations
in ganglioside expression could affect the tissue response against
the peptide induced cell death (via GSK3b more phosphorylated
and less active). Although the GM1 concentration used in this study
favors micelle formation and thereby facilitates its incorporation
into plasma membranes, such inclusion is still small (Rauvala,
1979; Ulrich-Bott and Wiegandt, 1984; Schwarzmann, 2001), so
that the neuroprotective effects here observed should be under-
stood as a result of exogenous administration of a bioactive mole-
cule, and not necessarily as a result of lipid content manipulation
of neural membranes. More studies are needed to investigate the
actual biological effect of ganglioside metabolism modulation
(especially GM1) triggered by Ab. If an increase of endogenous
GM1 content could result, like its exogenous administration, in
modulation o GSK3b and neuroprotection, on the other hand we
cannot rule out the hypothesis that a long-term change in neural
membrane content of this lipid could accelerate ﬁbrillogenesis.
At any rate, our work demonstrates the effect of Ab on the gan-
glioside expression, and although the interpretation of the role of
these alterations in AD has a still speculative nature, our data on
the GM1 neuroprotective effect reinforce the hypothesis that these
lipid changes may have an important biological signiﬁcance, rekin-
dling the interest in investigating the clinical use of GM1, or its
synthetic analogs, in the treatment of Alzheimer’s disease (Bira-
boneye et al., 2009; Avila et al., 2010).Acknowledgements
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